Quick Answer: Europe does not use one short universal “banned cosmetic words” list. EU rules prohibit cosmetic claims that imply characteristics or functions the product lacks, suggest approval by an EU competent authority, or present mere compliance with minimum legal requirements as a special benefit. Other claims can be unacceptable when false, unsupported, exaggerated, unfair or misleading in context. Disease-treatment or similar statements also require a product-classification review.
Last reviewed: 27 September 2026. Editorial review: MOOYAM cosmetic compliance content team. This is an educational risk-screening guide for B2B brands; any specific label, listing or campaign requires case-by-case review.
Start with the legal test, not a list of taboo words
Article 20 of Regulation (EC) No 1223/2009 applies to text, names, trademarks, pictures and other signs used in labelling, market presentation and advertising. A cosmetic must not be presented as having a characteristic or function it does not have. Commission Regulation (EU) No 655/2013 adds six common criteria: legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making.
That means the likely consumer impression matters. A phrase that seems qualified in a technical report may communicate a stronger promise when paired with a before-and-after image or retailer badge. Assess the full product name, pack, translations, website, marketplace listing and advertising asset rather than reviewing one isolated line of copy.
| Claim type | EU rule or boundary | What a brand should do |
|---|---|---|
| “EU authority approved this cosmetic” | Regulation 655/2013 explicitly disallows suggesting competent-authority approval | Remove the approval implication; do not confuse CPNP notification with approval |
| “Specially safe because it meets mandatory law” | Mere minimum legal compliance cannot be marketed as a special benefit | Describe genuine product-specific benefit only when supported |
| Disease-treatment promise | May raise classification issues beyond cosmetics | Seek qualified classification review before release |
Claims expressly ruled out by the common criteria
The legal-compliance criterion in Regulation 655/2013 explicitly disallows claims indicating that a product was authorised or approved by an EU competent authority. CPNP submission does not confer such approval. The same criterion disallows conveying a specific product benefit when it is only compliance with minimum legal requirements. Avoid badges, seals, wording or layouts that make an ordinary legal duty look like a voluntary quality distinction.
The truthfulness criterion also requires that a named ingredient be deliberately present. It disallows transferring an ingredient’s property to the finished cosmetic when the finished product does not have that property. For example, a laboratory observation about an isolated raw material cannot by itself establish that a marketed cream delivers the same outcome at its formulated concentration and use conditions.
High-risk claims that depend on evidence and context
A numerical efficacy claim such as “reduces visible lines by 40%” needs evidence suitable for the final product, test population, method and stated timeframe. An absolute claim such as “works for everyone” makes a very broad promise that is difficult to substantiate. A “clinically proven” or “dermatologist tested” statement should accurately describe what happened in the study rather than implying a stronger conclusion. These are illustrative claim-review scenarios, not an official EU blacklist of exact phrases.
Likewise, “natural,” “hypoallergenic,” “sensitive skin” and “free-from” are not uniformly prohibited words under Article 20. The brand must evaluate their meaning, accuracy, substantiation and fairness for the specific product and target audience. A “free-from” message should not unfairly denigrate a lawful ingredient or imply that legally marketed competitor products are unsafe without evidence. The European Commission legislation page links the official technical document on cosmetic claims; its examples can help interpretation but do not replace the binding regulation.
| Proposed message | Evidence question | Possible safer path |
|---|---|---|
| Contains a named active ingredient | Is the material deliberately present in the final formula? | Verify formula and accurately name the ingredient |
| Finished-product performance | Was the marketed SKU tested or is a valid bridge documented? | Limit wording to the result the evidence actually supports |
| Tested or certified claim | Who tested it, what was measured and which product version? | State the specific, verifiable test fact |
| No competitor ingredient | Is the absence true and presented fairly? | Avoid suggesting lawful ingredients are inherently unsafe |
| Universal or permanent result | Can the broad promise be substantiated for normal use? | Narrow the claim or do not use it |
Disease and medicinal implications require a separate classification decision
A product presented as treating or preventing a disease may fall outside the cosmetic framework. The Commission says borderline classification is made case by case, considering all product characteristics. See the official borderline-products guidance. Do not automatically assume that changing one verb fixes a claim when the product name, instructions and images still communicate a medical purpose.
This is especially important for acne, eczema, infection, wound-healing or other health-condition messaging. Some products in these categories may be regulated under other regimes depending on formulation, intended purpose and national interpretation. A cosmetic manufacturer should not promise that a product qualifies as a cosmetic merely because it can be manufactured in a cosmetic facility.
How should a brand screen a claim before launch?
1. Collect all versions of the claim, including visual and translated versions. 2. Define the intended and likely implied consumer takeaway. 3. Check that the product remains within the cosmetic category. 4. Map each factual element to the finished formula and appropriate evidence. 5. Apply all six criteria in Regulation 655/2013. 6. Have the EU Responsible Person review the approved wording and evidence in the Product Information File. 7. Lock the final asset and repeat the review when formula, tests, translations or marketing context changes.
For a full framework rather than specific red flags, see the companion EU cosmetic claims regulation guide. The EU Cosmetics Regulation overview explains why claim control belongs alongside the Responsible Person, CPSR, PIF, CPNP and labelling work. Claim support is not a substitute for finished-product safety assessment.
What can the manufacturer provide—and what remains with the brand?
MOOYAM can provide controlled formula and INCI records, product specifications, COA, SDS where applicable, stability and microbiological information, packaging-compatibility results and agreed test reports. Those documents help evaluate whether a factual or performance claim matches the finished product. The brand controls its positioning, artwork and channels; the EU Responsible Person must ensure the final wording meets EU criteria and matches the PIF. A supplier presentation cannot serve as blanket authorization for every brand campaign.
FAQ
Is “EU approved” acceptable after CPNP notification?
No. Regulation 655/2013 disallows indicating that an EU competent authority approved or authorised a cosmetic. CPNP is notification, not approval.
Are medical words automatically banned from every cosmetic ad?
Classification depends on the entire product presentation and context. Claims implying disease treatment can move a product outside cosmetic scope and need qualified review.
Can a brand say “clinically proven”?
Only if the evidence and context support the precise meaning conveyed. The phrase alone is not an EU approval and should not overstate the study.
Is “free-from” always prohibited?
No. It requires truthful, fair, context-specific review and should not unfairly denigrate lawful ingredients or competitors.
Does a raw-material supplier test prove a finished-product claim?
Not by itself. The brand and Responsible Person must examine whether the evidence can validly support the final formula and the exact consumer-facing promise.
Official sources
Regulation (EC) No 1223/2009, Article 20; Commission Regulation (EU) No 655/2013; European Commission cosmetics legislation and claims guidance; European Commission borderline-products guidance.
Manufacturer support: MOOYAM provides cosmetic OEM/ODM manufacturing and technical documentation support for international beauty brands. Request product-specific records and any agreed testing plan early enough for your EU Responsible Person to review the intended claim before artwork release.
Regulatory requirements may change. Brands should verify current requirements with the relevant regulatory authority or a qualified compliance professional before placing cosmetic products on the market.